ACE-LY-312 (D8227C00001) ESCALADE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤70 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma
Detalhes
Destaques